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ABSTRACT 
Objective: To compare risk of stillbirth between maternal smokers and those prescribed NRT during 
pregnancy. 
Design: Cross-sectional analysis nested in a pregnancy cohort with longitudinal routinely-recorded 
medical data 
Setting: United Kingdom primary care; The Health Improvement Network (THIN) general practice 
database 
Population: 220,630 singleton pregnancies ending in live or stillbirth, 2001-2012 
Methods: Women were categorised into three groups:  NRT (prescribed during pregnancy or one 
month before conception); smokers; controls (non-smokers without a pregnancy NRT prescription).  
Main Outcome Measure: odds ratios (OR) adjusted to maternal characteristics and 95% confidence 
intervals (CIs) for stillbirth 
Results: A total of 805 pregnancies ended in stillbirth (3.6/1,000 births). Absolute risks of stillbirth in 
NRT and smoker groups were both 5/1,000 births compared with 3.5/1,000 births in the control 
group. Compared with the control group, the adjusted odds of stillbirth in the NRT group was not 
statistically significant (OR=1.35, 95% CI 0.91-2.00), although it was similar in magnitude to that in 
the smokers group (OR=1.41, 95% CI 1.13-1.77).   
Conclusions: We found no evidence of a statistically significant association between being prescribed 
NRT during pregnancy and odds of stillbirth compared with non-smoking women.  Although our 
study had much larger numbers than any previously, an even larger study with biochemically-
validated smoking outcome data and close monitoring of NRT use throughout pregnancy is required 
to exclude effects on findings of potential exposure misclassification. 
Keywords: stillbirth, nicotine replacement therapy, smoking, pregnancy, maternal smoking 
Tweet abstract: No significant increase in stillbirth for women prescribed NRT in a UK study of 
220,710 pregnancies  
INTRODUCTION  
Maternal smoking during pregnancy increases the risk of several adverse birth outcomes including 
stillbirth. A meta-analysis of four studies from Australia, Sweden, Canada and the United States of 
America (USA) found maternal smoking to increase the risk of stillbirth by 36%.1 Despite this, 12% of 
pregnant women in the United Kingdom (UK),2 13% in the USA,3 and 15% in Australia4 still smoke 
during pregnancy. Therefore, reducing smoking during pregnancy is a global public health priority. 
Pharmacotherapy, specifically the use of Nicotine Replacement Therapy (NRT) is being adopted in 
several national guidelines for supporting pregnant smokers to quit, based on the notion that NRT is 
probably safer than smoking.5-7 In the UK, approximately 11% of pregnant smokers are prescribed 
NRT in primary care,8 despite a lack of evidence concerning its safety in pregnancy.9  Evidence 
specifically in relation to stillbirth is limited to one population-based study using the Danish National 
Birth Cohort (DNBC) which found no increased risk of stillbirth associated with NRT use in the first 27 
weeks of pregnancy (hazard ratio (HR) = 0.57, 95% Confidence Interval (CI) 0.28-1.16 compared to 
those who did not use NRT and did not smoke). Information on NRT use and smoking status in the 
DNBC was ascertained up to the time of interview, at approximately 17 weeks gestation, so it is 
possible that women’s exposure status may have changed during the second or third trimesters. A 
meta-analysis of four randomised controlled trials (RCTs) assessing stillbirth as a secondary outcome 
reported a raised but not significant pooled risk ratio (RR) of 1.24 (95% CI 0.54-2.84) for NRT use 
compared with placebo.10 However RCTs assessing effectiveness of NRT patches and gum for 
quitting do not provide such safety evidence as they have inadequate power to assess rare 
outcomes. 11-13 
In light of limited safety evidence, in its recent international guidelines on prevention and 
management of tobacco use in pregnancy, the World Health Organization (WHO) recognised an 
urgent need for more research into the effects of NRT on pregnant women and the fetus, along with 
its efficacy.14 Therefore, using a large population-based pregnancy cohort we investigated whether 
NRT prescribed in UK primary care is associated with stillbirth, compared with pregnant women 
recorded as smokers not prescribed NRT and a non-smoker control group.  
 
METHODS 
Data source and study population 
The Health Improvement Network (THIN) is a UK database of anonymised electronic primary care 
records, including sociodemographic information, diagnoses, prescriptions and investigations. The 
validity of recorded diagnoses and prescriptions is high15 and THIN has been previously validated for 
its recorded population prevalence of smoking at a national level for both the general population 16 
and pregnant women.17 Furthermore, fertility rates in THIN are highly comparable to national 
fertility rates.18  At the time of this study, THIN contained longitudinal prospectively-collected data 
from 570 general practices across the UK, covering 6% of the UK population.19 We created our study 
population extracting all the singleton pregnancies with deliveries between 2000 and 2013. 
Exposure 
All pregnant women with a recorded prescription for NRT during pregnancy in their primary care 
records were identified, using Multilex drug codes for all formulations available in the UK according 
to the British National Formulary (BNF),20 and classified as the NRT group, provided they didn’t have 
a current smoking Read code following the NRT prescription. Women with a prescription for NRT in 
the four weeks before conception were also included in the NRT group because it is likely that the 
medication could have been consumed during the early stages of pregnancy. Smoking status during 
pregnancy was determined from a previously-validated algorithm using smoking status Read 
codes.16,17 Using this algorithm, we categorised women as smokers (those recorded as smokers at 
any point from conception until delivery) or controls (those exclusively recorded as non-smokers at 
any point from conception until delivery). In 2004, the introduction of the Quality and Outcomes 
Framework (QOF) brought several pay-for-performance targets to primary care, including the 
electronic recording of smoking and smoking cessation advice. Since these data are recorded in 
routine primary care where repeat recordings for ex and never smokers are not required in certain 
scenarios, use of these QOF rules further facilitated identification of controls.21 Firstly, if there was 
no smoking status record during pregnancy, but women were recorded as never smokers at any time 
during their active registration period when they were over 25 years of age, they were included in 
the control group. Secondly, if a woman did not have a smoking status record during pregnancy but 
was recorded as an ex-smoker for three consecutive years before pregnancy, we categorised her as 
an ex-smoker and she was thus included in the control group. After considering these QOF rules all 
remaining women with missing smoking status were excluded from the study. More details on this 
approach of defining non-smoking controls have been previously published.9  
 
Outcome 
Stillbirth was defined as a baby born with no signs of life at or after 28 weeks of gestation, in 
accordance with the WHO definition.22 Information on the following potential confounders was also 
extracted due to known associations between these factors/conditions or their treatments and both 
stillbirth and maternal smoking:23-31 women’s age at conception; socioeconomic deprivation (quintile 
of the Townsend Index of deprivation);32  pre-pregnancy body mass index (BMI); and recorded 
diagnoses of medical conditions before or during pregnancy (hypertension, epilepsy, diabetes, 
asthma, and mental illness including depression, anxiety, bipolar disorder, schizophrenia and other 
psychoses). All code lists are available from the authors on request.  
 
Statistical analysis 
The absolute risk of stillbirth was calculated as the total number of stillbirths divided by the number 
of stillbirths and live births combined. This was estimated for the entire population as well as each 
exposure group (i.e. NRT group, smokers and controls). We used logistic regression to compute odds 
ratios (OR) and corresponding 95% confidence intervals (CI) for stillbirth for the NRT group and 
smokers, compared with the control group.  All potential confounders that had a statistically 
significant association (p<0.05) with the exposure and the outcome in chi-squared tests were 
included in the final model. Some women in the study period had more than one pregnancy and 
therefore we used generalised estimating equations with an exchangeable correlation structure to 
take potential correlation between pregnancies into account.33 The reference group was then 
changed to smokers and the ORs and corresponding 95% CIs were re-calculated. All analysis was 
conducted in Stata MP 12 (Stata Corp., College Station, TX). 
RESULTS 
Baseline characteristics 
The study population included 220,630 singleton pregnancies delivered from 2001 to 2012, of which 
805 ended in stillbirth, a prevalence of 3.6 per 1,000 births. Table 1 presents the baseline 
characteristics of mothers overall and by birth outcome. Pregnancies that were conceived at later 
maternal ages (≥35 years) resulted in a higher prevalence of stillbirth. Diabetes was also more 
common in pregnancies that ended in stillbirth compared to live births (5.0%vs. 3.2%). The 
distribution of socioeconomic status, and the prevalence of other chronic illnesses like asthma, 
hypertension and mental illness were comparable in women with stillbirth and those with live births. 
For women with an NRT prescription, the average duration of NRT prescription was 2 weeks 
(Interquartile range: 6 days- 2weeks) and 80% of NRT prescriptions were recorded within the first 
two trimesters.  
Table 2 presents the characteristics of mothers according to each exposure group. Mothers in the 
smoking and NRT group were considerably younger compared with the control group. About half of 
the mothers in the NRT and smoking group belonged to the two most deprived quintiles compared 
to about a quarter in the control group. In addition, there was a higher proportion of mothers in the 
NRT and smoking groups with mental illness compared with the control group (20.0%, 16.0% and 
7.8% respectively). 
Absolute and relative risks of stillbirth 
Table 3 presents the absolute and relative risks of stillbirth by each exposure group. The absolute 
risk of stillbirth in the NRT group as well as amongst smokers was 5 per 1000 births, compared to 3.5 
per 1000 births in the control group. In the unadjusted analysis, NRT was associated with a 44% 
increase in the odds of stillbirth compared with the reference group that was not statistically 
significant (OR 1.47, 95% CI 0.97-2.14) whilst smoking was associated with a statistically significant 
52% increase in the risk of stillbirth (OR 1.52, 95% CI 1.23-1.89). After adjusting for potential 
confounders including maternal age, socioeconomic status, pre-pregnancy body mass index and 
diabetes, there was still no statistically significant increase in the risk of stillbirth in the NRT group in 
comparison with the control group (OR 1.35, 95% CI 0.91-2.00), however, smoking during pregnancy 
was still associated with a 41% statistically significant increased risk of stillbirth (OR 1.41, 95% CI 
1.13-1.77).  When the reference group was changed to smokers, there was still no statistically 
significant association between NRT and stillbirth (OR 0.95, 95% CI 0.62-1.48). 
DISCUSSION 
Main findings 
Using 220,630 singleton pregnancies we found the absolute risk of stillbirth was very similar 
between the NRT and smoker groups. Although the effect estimates for both NRT and smoking were 
very similar, we found no statistically significant association between NRT being prescribed during 
pregnancy and stillbirth. Women who smoked during pregnancy had a 41% increased risk of stillbirth 
compared to the control group, which included never smokers as well as ex-smokers. 
 
Strengths and limitations 
This is the largest study to date to investigate the association between NRT prescribing in pregnant 
women and stillbirth. However, due to the low prescribing of NRT in pregnancy,8 an even larger 
sample size is required to assess the association with adequate power. Stillborn babies are usually 
not registered in primary care. Therefore, the ascertainment of stillbirth in this study is based on the 
documentation of such events in maternal primary care records. Approximately 97% of deliveries in 
England and Wales in 2011 took place in NHS hospitals, maternity units and maternity wings34 and all 
the delivery information recorded in inpatient data should, but may not always, be transferred into 
primary care records. Therefore, we may have missed cases of stillbirth. Nevertheless, the 
prevalence of stillbirth in this study was 3.6/1,000 live and stillbirths, which is comparable to the 
national prevalence of 5.2/1,000 births in the UK.35 This slightly lower rate of stillbirth in THIN 
compared to the national prevalence may be attributed to the slight under-representation of 
general practices from more socioeconomically deprived areas in THIN. The effects of smoking or 
NRT use during pregnancy on stillbirth may be mediated by outcomes such as congenital 
anomalies,36 however, comprehensive data on congenital anomalies in these stillbirths are not 
available as a very small proportion of congenital anomalies are diagnosed antenatally and it is not 
routine conduct a full autopsy after stillbirth for a full diagnosis of congenital anomalies. 
Furthermore, in our earlier work we found no statistically significant increased risk for major 
congenital anomalies associated with NRT use.9  
We used primary care records to ascertain NRT exposure which is a more objective measurement of 
drug prescribing and use during pregnancy than self-reports by mothers in other studies.37,38 We 
recognise, however, the inherent inaccuracy in ascertaining true drug exposure in observational 
studies. In the UK, pregnant women can access NRT in settings other than the GP practice, such as 
through NHS Stop Smoking Services for Pregnancy (SSSP), over-the-counter purchases in 
pharmacies, and off-the-shelf purchases in supermarkets. However, only 3% of pregnant women 
access an SSSP on average each year39,40 and a survey of all SSSPs in England conducted between 
April 2010 and March 2011 reported that almost half of the NRT provided by these services was 
issued through GPs.41 Furthermore, the prevalence of medication use without prior consultation 
with a health professional is lower during pregnancy than when women are not pregnant;42 NRT 
packaging clearly instructs pregnant women to consult a doctor before using these and, in the UK, 
women are entitled to free NHS prescriptions during pregnancy.43 Therefore, we believe that self-
purchase of NRT would be infrequent in this group and misclassification in the exposure 
measurement should be minimal; however, the true magnitude of exposure misclassification is 
potentially unquantifiable and therefore results should be interpreted with caution. Since 2010, in 
addition to its use for smoking cessation NRT has been indicated for harm reduction, such that 
smokers could use NRT to cut down on smoking. Nevertheless, this indication does not apply to 
pregnant women. Therefore, we believe that simultaneous use of NRT and cigarettes should be 
minimal. Measuring concurrent usage in an epidemiological study would only be possible with a 
detailed follow-up study which would need to have multiple prospective recordings of women’s 
smoking behaviour and close behaviour monitoring. Another potential concern is that prescriptions 
issued are not necessarily an indication of compliance to drug therapy and some of the prescriptions 
issued may not have been redeemed. Similarly, smoking cessation does not necessarily follow being 
prescribed with NRT and some women in receipt of prescriptions may have continued to smoke.  
However, a validation study comparing the recorded prescriptions for smoking cessation 
medications in THIN and the NHS dispensing data between January 2004 and December 2005 
reported good comparability between the two data sources indicating that prescriptions recorded 
for smoking cessation medications in primary care data are collected by the patients.44 Furthermore, 
measuring actual drug consumption in any large population-based study is pragmatically difficult and 
is a limitation in previous studies as well.37  
Accurate ascertainment of smoking status is also difficult, especially in pregnant women, due to the 
social stigma attached to smoking. However, all previous epidemiological studies investigating the 
association between maternal smoking and stillbirth have similarly relied on self-reported smoking 
status data, as biochemical validation of large samples is expensive and often practically prohibitive 
throughout pregnancy. In our study smoking status was self-reported in primary care and recorded 
during pregnancy by doctors, nurses or midwives.  Smoking prevalence from THIN based on the QOF 
rules, using information recorded within 27 months before pregnancy shows good agreement with 
smoking estimates from other national datasets including the Scottish Morbidity Record and the 
Child Health Systems Programme data. 17 Self-reports of smoking habit to health professionals 
invested in the person’s clinical care have shown to be reasonably accurate compared with those in 
bespoke studies.45  
 
Interpretation in light of other evidence 
Our study found no statistically significant increased risk of stillbirth associated with NRT exposure 
during pregnancy. The study of 87,032 pregnancies from the Danish National Birth Cohort (DNBC), 
had information on smoking and NRT use that was self-reported by women during an interview at 
approximately 17 weeks gestation. For women who used NRT there was no statistically significant 
increase in the risk of stillbirth (HR 0.57, 95% CI 0.28-1.16) compared to non-users.46 Furthermore, 
compared to non-smokers and non-NRT users (i.e. controls) the HR for stillbirth among women who 
smoked and used NRT simultaneously was 0.83 (95% CI 0.34-2.00) and among non-smokers who 
used NRT was 0.67 (95% CI 0.21-2.08). However, the non-smoker group in their study included ex-
smokers who quit before conception but also women who were smoking during pregnancy but not 
at the time of the interview and therefore it is quite difficult to exclusively differentiate between the 
two, which could potentially result in misclassification of the exposure. They also did not have 
information on smoking or NRT after the interview so this is also a potential source of exposure 
misclassification. Furthermore, the time periods to define stillbirth were considerably different 
between both the DNBC study and our study: the DNBC study classified stillbirth as any fetus that 
did not breathe or show any other sign of life at birth after a minimum of 20 weeks of gestation 
compared to 28 weeks in our study. The potential differences between the exposure window and 
definition of stillbirth and the small number of stillbirth cases in the NRT group (n=8) in the DNBC 
study could potentially explain the difference in findings. Nevertheless, our results are also in line 
with the pooled estimates from a meta-analysis of RCT data (RR 1.24, 95% CI 0.54-2.84),10 again 
suggesting that the use of NRT does not significantly increase or reduce the risk of stillbirth.   
Whilst the effect estimates for NRT and smoking were very similar we found a 41% statistically 
significant increase in the risk of stillbirth in smokers. Exposure misclassification or residual 
confounding could be potential explanations or it could be that nicotine whether in the form of NRT 
or cigarette has a very similar effect on the growing fetus. Nevertheless, the statistically significant 
association between smoking and stillbirth is consistent with the current literature. The DNBC study 
found the risk of stillbirth to be 46% higher in smokers (HR 1.46, 95% CI 1.17-1.82) compared to non-
smokers using smoking information from the first trimester.46 Similarly, another Danish study based 
on a cohort of 25,102 live born singleton children collected smoking data before 30 weeks of 
gestation and found the risk of stillbirth to be twice as high compared to non-smokers.47 Other 
studies that assessed smoking at the end of pregnancy or where the exact time of smoking 
assessment was not specified found the risk of stillbirth in smokers to be between 34%48  and over 
two fold  1,24,47,49,50 higher compared to non-smokers.  
Tobacco smoke contains many harmful chemicals including nicotine, carbon monoxide, nitrogen 
oxides51,52 and  reduces fetal oxygenation through increased blood levels of carboxyhaemoglobin 
and impairment of oxygen unloading.47  This, along with prostacyclin synthesis, increases vascular 
resistance and decreases fetal blood flow. All these effects combined with the postulated 
vasoconstriction through nicotine47 could collectively result in fetal growth restriction and placental 
complications, which are the most important causes of stillbirth.53,54 However, we found the effect 
estimates in the NRT and smoking group to be very similar and when compared directly to maternal 
smoking the risk estimates for stillbirth were not higher in the NRT group. Another potential 
explanation for the similar effect estimates in both groups is that pregnant women in the sample 
may have used only short courses of NRT (~2 weeks); long-term adherence with NRT in pregnancy 
has been poor in other studies. Data from the Smoking, Nicotine and Pregnancy trial also show that 
only 7.2% women in the NRT group and 2.8% in the placebo group continued to use NRT beyond one 
month.11  Therefore, although we ensured that women prescribed NRT had no subsequent records 
of smoking throughout pregnancy, it is possible that some women did recommence smoking but did 
not report it to their GP or midwife. 
Conclusion 
Previous evidence on maternal NRT exposure during pregnancy and the risk of stillbirth is limited 
and inconclusive. In the present study, with much larger numbers than others, we did not find a 
protective or harmful effect of NRT prescribed during pregnancy as part of routine clinical care, in 
relation to stillbirth. Whilst there may be no true association between NRT exposure during 
pregnancy and stillbirth, the potential impacts of residual confounding, misclassification of the 
exposure and limited power must be recognised. An even larger study with biochemically-validated 
data on active and passive smoking exposures, including close monitoring of independent NRT use as 
well as concurrent use with smoking throughout the 9 months of pregnancy, is required to 
determine this more definitively. 
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 Table 1 - Baseline characteristics of the study population by outcome 
 All pregnancies 
(N=220,630) 
Pregnancies 
ending in live 
birth 
(N=219,825) 
Pregnancies 
ending in 
stillbirth 
(N=805) 
p-value 
 n % n % n % 
Age at conception        
15-19 years 9,731 4.4% 9,684 4.4% 47 5.8%  
20-24 years 32,585 14.8% 32,453 14.8% 132 16.4%  
25-29 years 58,649 26.6% 58,459 26.6% 190 23.6%  
30-34 years 70,605 32.0% 70,393 32.0% 212 26.3% <0.001 
35-39 years 40,210 18.2% 40,043 18.2% 167 20.7%  
40-44 years 8,406 3.8% 8,352 3.8% 54 6.7%  
45-49 years 444 0.2% 441 0.2% 3 0.4%  
Townsend score in quintiles        
Quintile 1 (least deprived) 48,205 21.8% 48,071 21.9% 134 16.6%  
Quintile 2 41,210 18.7% 41,064 18.7% 146 18.1%  
Quintile 3 43,584 19.8% 43,411 19.7% 173 21.5% 0.001 
Quintile 4 40,455 18.3% 40,300 18.3% 155 19.3%  
Quintile 5 (most deprived) 29,431 13.3% 29,294 13.3% 137 17.0%  
Missing  17,745 8.0% 17,685 8.0% 60 7.5%  
Pre-conception Body Mass 
Index (kg/m2) 
       
Normal(18.5-24.9) 81,408 36.9% 81,157 36.9% 251 31.2%  
Underweight(<18.5) 5,445 2.5% 5,424 2.5% 21 2.6%  
Overweight(25-29.9) 39,959 18.1% 39,796 18.1% 163 20.2% 0.001 
Obese(>=30) 28,308 12.8% 28,174 12.8% 134 16.6%  
missing 65,510 29.7% 65,274 29.7% 236 29.3%  
Asthma 22,444 10.2% 22,368 10.2% 76 9.4% 0.491 
Hypertension 6,502 2.9% 6,472 2.9% 30 3.7% 0.190 
Diabetes 7,076 3.2% 7,036 3.2% 40 5.0% 0.004 
Mental Illness 19,344 8.8% 19,273 8.8% 71 8.8% 0.958 
 
 
 
 
Table 2- Baseline characteristics of the study population by exposure status 
 All pregnancies 
(N=220,630) 
Control Group 
(N=197,002) 
Smokers 
(N=18,407) 
NRT Group 
(N=5,221) p-value 
 n % n % n % n % 
Age at conception          
15-19 years 9,731 4.4% 6,890 3.5% 2,384 13.0% 457 8.8%  
20-24 years 32,585 14.8% 26,095 13.2% 5,211 28.3% 1,279 24.5%  
25-29 years 58,649 26.6% 52,440 26.6% 4,755 25.8% 1,454 27.8%  
30-34 years 70,605 32.0% 65,794 33.4% 3,636 19.8% 1,175 22.5% <0.001 
35-39 years 40,210 18.2% 37,582 19.1% 1,931 10.5% 697 13.3%  
40-44 years 8,406 3.8% 7,797 4.0% 456 2.5% 153 2.9%  
45-49 years 444 0.2% 404 0.2% 34 0.2% 6 0.1%  
Townsend score in quintiles          
Quintile 1 (least deprived) 48,205 21.8% 45,900 23.3% 1,792 9.7% 513 9.8%  
Quintile 2 41,210 18.7% 38,369 19.5% 2,195 11.9% 646 12.4%  
Quintile 3 43,584 19.8% 39,024 19.8% 3,541 19.2% 1,019 19.5% <0.001 
Quintile 4 40,455 18.3% 34,236 17.4% 4,805 26.1% 1,414 27.1%  
Quintile 5 (most deprived) 29,431 13.3% 23,348 11.9% 4,816 26.2% 1,267 24.3%  
Missing  17,745 8.0% 16,125 8.2% 1,258 6.8% 362 6.9%  
Pre-conception Body Mass Index 
(kg/m2) 
         
Normal(18.5-24.9) 81,408 36.9% 74,752 37.9% 5,101 27.7% 1,555 29.8%  
Underweight(<18.5) 5,445 2.5% 4,681 2.4% 606 3.3% 158 3.0%  
Overweight(25-29.9) 39,959 18.1% 36,446 18.5% 2,662 14.5% 851 16.3% <0.001 
Obese(>=30) 28,308 12.8% 25,444 12.9% 2,214 12.0% 650 12.4%  
Missing 65,510 29.7% 55,679 28.3% 7,824 42.5% 2,007 38.4%  
Asthma  22,444 10.2% 19,565 9.9% 2,227 12.1% 652 12.5% <0.001 
Hypertension 6,502 2.9% 6,028 3.1% 368 2.0% 106 2.0% <0.001 
Diabetes 7,076 3.2% 6,518 3.3% 418 2.3% 140 2.7% <0.001 
Mental Illness 19,344 8.8% 15,350 7.8% 2,952 16.0% 1,042 20.0% <0.001 
Table 3 - Absolute and relative risks of stillbirth for NRT and smoking groups compared to controls 
  Absolute risk of stillbirth  Unadjusted OR (95% CI) p-value Adjusted OR (95% CI)* p-value 
n % 
Control Group 683  0.35 Reference 
 
Reference 
 
NRT group 26 0.50 1.44 (0.97-2.14) 0.069 1.35 (0.91-2.00) 0.139 
Smokers 96 0.52 1.52 (1.23-1.89) <0.001 1.41 (1.13-1.77) 0.003 
*adjusted for maternal age, socioeconomic status, pre-pregnancy body mass index and diabetes 
 
 
 
 
 
